Drug Trial Radar · NCT07928661
Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jul 29, 2026
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Universitas SriwijayaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to determine whether Proliverenol supplementation can improve liver fat levels and blood sugar control in patients with type 2 diabetes. Participants will be divided into two groups: one group will receive Proliverenol with standar therapy of DM, and the other only receive standar therapy of DM. The study will last for 12 weeks, and participants will undergo blood tests and liver examinations."
Conditions
- Diabetes Mellitus, Type 2
Interventions
ProliverenolDrug
This is the first study to evaluate Proliverenol specifically in patients with type 2 diabetes."
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the Visceral Adiposity Index (VAI) from baseline to week 12Time frame: Baseline and week 12
- Change in HOMA-IR from baseline to week 12Time frame: Baseline and week 12
- Change in C-Peptide from baseline to week 12Time frame: Baseline and week 12
- Change in Controlled Attenuation Parameter (CAP) from baseline to week 12Time frame: Baseline and week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Sriwijaya Palembang
Palembang, South Sumatera, Indonesia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.